MIR Acquisition, an Ann Arbor-Michigan-based company that operates as Molecular Imaging Research Inc. and specializes in the in vivo preclinical imaging of small animals, has closed a $7m Series A venture financing.
The company intends to use the funding to expand and commercialize its technology, which is used by pharmaceutical, biotechnology and medical devices companies.
MIR focuses on oncology and is extending its efforts to other therapeutic areas. It has performed over 250 imaging studies since 2003.
In conjunction with the funding, Pete Shagory, Partner at Baird Venture Partners, and James Dougherty, MD of Arcus Ventures, will join MIR’s Board of Directors. Tom Ludlam, Jr. has joined the company as President and CEO.